Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 mei 2013 - 07:38
Statutaire naam
Galapagos NV
Titel
Galapagos business update
Bericht
Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) announced today that the operational and financial results achieved thus far in 2013 encourage the Company to retain full year 2013 Group revenues guidance of €160 million.
"Galapagos has a maturing and broad pipeline of novel mode of action programs. Our flagship program, GLPG0634, will start a large Phase 2b study next month, and both we and our partner AbbVie are excited about the opportunities of this molecule for the safe treatment of rheumatoid arthritis and other inflammatory diseases," said Onno van de Stolpe, CEO of Galapagos. "In our development portfolio, we now have three programs in Phase 2 studies in four inflammation disease areas, and we are well on track to having multiple Phase 1 programs with novel, proprietary modes of action by end 2013."
Datum laatste update: 01 september 2024